Publish in this journal
Journal Information
Vol. 11. Issue 4.
Pages 204-209 (July - August 2015)
Share
Share
Download PDF
More article options
ePub
Visits
941
Vol. 11. Issue 4.
Pages 204-209 (July - August 2015)
Original Article
DOI: 10.1016/j.reumae.2014.08.002
Factors associated with treatment of osteoarthritis: Analysis of a COPCORD study in Nuevo León, México
Factores asociados al tratamiento de osteoartritis: análisis de un estudio COPCORD en Nuevo León, México
Visits
941
Alexia Estefanía Hernández-Cáceresa, Jacqueline Rodriguez-Amadoa, Ingris Peláez-Ballestasb, David Vega-Moralesa, Mario Alberto Garza-Elizondoa,
Corresponding author
mariogarz@hotmail.com

Corresponding author.
a Department Internal Medicine, Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Nuevo León, Mexico
b Department of Rheumatology, Hospital General de México “Dr. Eduardo Liceaga”, Ciudad de México, Distrito Federal, Mexico
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (4)
Table 1. Baseline demographic characteristics.
Table 2. Univariate analysis between the groups who did/did not received treatment.
Table 3. Univariate analysis of the employed treatment.
Table 4. Multivariate analysis of the variables associated with treatment.
Show moreShow less
Abstract
Introduction

Osteoarthritis (OA) is the most prevalent rheumatic disease in Mexico. Treatment involves pharmacological and non-pharmacological strategies.

Objective

To describe the factors associated with treatment of osteoarthritis in the urban and rural population of Nuevo León.

Methods

Analysis of a cross-sectional study of patients with OA from a COPCORD study database. Univariate and multivariate analyses of the variables associated with treatment of OA.

Results

We included 696 patients with OA with an average age of 58 years (SD 14.1), 484 (69.5%) women. Pain with a visual analog scale (VAS) ≥4 was present in 507 (72.8%) patients. Functional disability was present in 133 (19%) patients and a mean HAQ of 0.37 (IQR 0.75) was found. The most frequent place of OA was knee in 356 (51.1%) patients; 259 (37%) patients already knew their diagnosis. The most employed treatments were non-steroidal anti-inflammatory drugs (289 patients, 58.5%). The variables associated with treatment were age >58 years (OR 1.3, 95% CI 1.0–1.5), female gender (OR 1.17, 95% CI 1.0–1.3), VAS pain ≥4 (OR 1.3, 95% CI 1.1–1.4), functional disability (OR 2.6, 95% CI 1.6–4.1), HAQ >0.375 (OR 1.9, 95% CI 1.5–2.4), and past diagnosis of OA (OR 5.1, 95% CI 3.3–8.0). In the multivariate analysis, VAS pain ≥4 (OR 1.9, 95% CI 1.2–2.8), kneeling disability (OR 3.15, 95% CI 1.3–7.4) and previous diagnosis of OA (OR 7.6, 95% CI 4.5–12.9) had statistical significance.

Conclusion

factors associated with treatment of OA are VAS pain ≥4, kneeling disability and previous diagnosis of OA.

Keywords:
Musculoskeletal diseases
Osteoarthritis
Epidemiology
Risk factors
Therapeutics
Resumen
Introducción

La osteoartritis (OA) es la enfermedad reumática más prevalente en México. El tratamiento involucra intervenciones farmacológicas y no farmacológicas.

Objetivo

Describir los factores asociados al tratamiento de osteoartritis en comunidades urbanas y rurales de Nuevo León.

Métodos

Estudio transversal analítico de pacientes con OA, obtenido de la base de datos del estudio COPCORD. Análisis univariado y multivariado de las variables asociadas al uso de tratamiento.

Resultados

Se incluyó a 696 pacientes, edad media ± desviación estándar de 58 ± 14,1 años, 484 (69.5%) mujeres. El dolor con intensidad ≥ 4 en escala visual analógica (EVA) se presentó en 507 (72,8%) individuos. En 133 (19%) individuos se presentó limitación física, con una mediana en HAQ de 0,37 (RIQ 0,75). La localización más frecuente de OA fue rodilla en 356 (51,1%) pacientes; 259 (37%) individuos ya tenían el diagnóstico de OA. El tratamiento más empleado fueron los antiinflamatorios no esteroideos en 289 (58,5%) individuos. Las variables asociadas al uso de tratamiento fueron edad >58 años (OR = 1,3, IC del 95%, 1,0-1,5), género femenino (OR = 1,1, IC del 95%, 1,0-1,3), dolor con EVA ≥ 4 (OR = 1,3, IC del 95%, 1,1-1,4), limitación fisica (OR = 2,6, IC del 95%, 1,6-4,1), HAQ >0,375 (OR = 1,9, IC del 95%, 1,5-2,4) y antecedente de diagnóstico de OA (OR = 5,1, IC del 95%, 3,3-8,0). En el multivariado, el dolor con EVA ≥ 4 (OR = 1,9, IC del 95%, 1,2-2,8), la incapacidad para arrodillarse (OR = 3,1, IC del 95%, 1,3-7,4) y el antecedente de diagnóstico de OA (OR = 7,6, IC del 95%, 4,5-12,9) permanecieron significativos.

Conclusión

Los factores asociados al tratamiento de OA son EVA del dolor ≥ 4, la incapacidad para arrodillarse y el antecedente de diagnóstico de OA.

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Precio 22,50 €

Comprar ahora
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.